Sharlene M. Day - Case Western Reserve University · 2017-01-10 · 7/2006 - present Director, Program for Hypertrophic and Other Inherited Cardiomyopathies 1/2013 - present Faculty,

Sharlene M. Day Associate Professor, Instructional Track, Internal Medicine

1150 W. Medical Center Drive 7301 MSRB III

Ann Arbor, MI 48109-0644 734-615-7917

[email protected] Education and Training

9/1987-5/1991 Bachelor of Science in Biology, Massachusetts Institute of Technology 8/1991-6/1995 M.D., New York University School of Medicine 7/1995-6/1998 Residency in Internal Medicine, University of Michigan 7/1998-6/2001 Fellowship in Cardiovascular Medicine, University of Michigan 7/2000-9/2000 Postdoctoral Training Course, Instructor: Steven Weiss, MD 9/2000-7/2002 Research Fellowship, Division of Cardiology, University of Michigan. Mentor:

William P. Fay, MD 7/2002-6/2005 Research Fellowship, Department of Physiology, University of Michigan. Mentor:

Joseph Metzger, PhD Certification and Licensure

1995 National Board of Medical Examiners 1998-present Medical Licensure, State of Michigan 1998 Diplomate, American Board of Internal Medicine 2001 Diplomate, Cardiovascular Disease 2011 Recertification, Cardiovascular Disease

Academic, Administrative, and Clinical Appointments

12/2001- 7/2005 Clinical Lecturer/Research Fellow, Department of Internal Medicine 7/2005 – 8/2013 Assistant Professor, Instructional Track, Internal Medicine

7/2006 - present Director, Program for Hypertrophic and Other Inherited Cardiomyopathies 1/2013 - present Faculty, Cell and Molecular Biology Program 9/2013 - present Associate Professor with Tenure, Internal Medicine 1/2014-present Associate Professor, Molecular and Integrative Physiology

Research Interests

1. Disease mechanisms in hypertrophic cardiomyopathy 2. Genotype-phenotype correlations in hypertrophic cardiomyopathy 3. Exercise in hypertrophic cardiomyopathy 4. Human stem cell-derived cardiomyocyte models of hypertrophic cardiomyopathy 5. Regulation of protein degradation and turnover in cardiomyopathies 6. Interventions to target cardiac aging

Grants a) Present and Active Grants

Sharlene M. Day, MD Page 2

1/2015-12/2019 NIH R01 GRANT11572784 Role: Co-PI (Other Co-PIs: Rachel Lampert, Michael Ackerman) Title: Exercise in Genetic Cardiovascular Conditions $869,968 DC/year 5/2013-4/2018 NIH 1P50HL112349-01 Role: Site Principal Investigator (PI: Carolyn Ho, Brigham and Women’s Hospital)

Using Genetics for Early Phenotyping and Prevention of Hypertrophic Cardiomyopathy $1,514,999

1/2017-12/2018 American Heart Association Grant in Aid Role: Principal Investigator Title: Disruption of Proteostasis in Hypertrophic Cardiomyopathy Caused by Truncating Mutations in Myosin Binding Protein C $77,000 total direct costs per year

7/2014-6/2017 American Heart Association Grant in Aid Role: Co-investigator (PI: Edward Miller) Title: Targeting the Immunoproteasome: A New Paradigm for the Treatment of Heart Failure $66,000 total direct costs per year, subcontract $25,000 direct costs per year 9/2016-8/2018 NRSA F31 Predoctoral Fellowship Award Role: Sponsor (PI: Amelia Glazier) Title: The role of Hsp70 chaperones in MYBPC3-linked Hypertrophic Cardiomyopathy $28,000 total direct costs per year 2/2014-1/2017 Amgen

Role: Co-Principal Investigator Pilot Studies of the Efficacy of Onyx-0914 to Improve Cardiac Function in Heart Failure $35,000

11/2013-1/2019 MyoKardia, Inc Role: Site Principal Investigator The Sarcomeric Human Cardiomyopathies Registry (SHaRe) $50,000 (per year) 9/2016-8/2017 Glenn Foundation CFSAM Pilot Award Role: Sub-project PI (Overall PI, Dr. Richard Miller) Effects of Acarbose on Healthspan and Cardiac Aging $50,000 4/2015-3/2017 Israel Partnership for Research, Collaborative Research Grant Role: co-PI (with Michael Glickman) Proteasome Disassembly and Dysfunction in Heart Failure $50,000 3/2016-2/2017 Biomedical Research Council Award Role: PI


Proteostasis in Hypertrophic Cardiomyopathy $50,000 6/2015-5/2017 Liz and Eric Lefkofsky Innovation Research Fund Role: co-PI (with Todd Herron) Title: Adult Human Stem Cell Microtissues as a Platform to Test Novel Heart Disease Therapies $75,000 per year for each PI 7/2014-present Taubman Scholar Award

A. Alfred Taubman Medical Research Institute, University of Michigan Role: Principal Investigator

Disease Mechanisms in Hypertrophic Cardiomyopathy $150,000 per year (Y1-3), $50,000 per year (Y3-6), $5,000 per year (Y7-) 7/2013-6/2018 Center for Protein Folding Diseases University of Michigan Fast Forward Initiative $1,405,513 per year, $25,000 per year allocated to Day lab b) Previous Grants

7/2015-9/2016 American Heart Association Predoctoral Fellowship Award Role: Sponsor (PI: Amelia Glazier) Title: The role of Hsp70 chaperones in MYBPC3-linked Hypertrophic Cardiomyopathy $26,000 total direct costs per year (2nd year relinquished due to NRSA award) 1/2015-12/2015 Children’s Cardiomyopathy Foundation Role: Principal Investigator Title: Disease Mechanisms for Myosin Binding Protein C Mutations in Hypertrophic

Cardiomyopathy $50K total direct costs per year 8/2009-5/2014 NIH R01 HL093338-01 Role: Principal Investigator Regulation of Proteasome Function in Cardiomyopathies

$250,000 (direct costs per year)

7/2011-6/2014 American Heart Association Clinical Research Program Role: Mentor (PI is Sara Saberi, University of Michigan)

Exercise as a Preemptive Strategy in Preclinical Hypertrophic Cardiomyopathy

5/2013-8/2013 American Heart Association Midwest Affiliate Undergraduate Student Research Fellowship Role: Mentor (PI is Vi Tang, Fairleigh Dickinson University, New Jersey)

Mechanisms for Proteasome Dysfunction in Hypertrophic Cardiomyopathy Associated with Myosin Binding Protein C Mutations

8/2013-4/2015 University of Michigan Cardiovascular Center Inaugural Grant Fund Role: Co-Principal Investigator


$25,000 The Role of Calcium Calmodulin-Dependent Protein Kinase II (CaMKII) in Hypertrophy and

Arrhythmias in Hypertrophic Cardiomyopathy 5/2014-4/2015 University of Michigan Cardiovascular Center Microgrant Role: Principal Investigator $5,000

Functional Consequences of a Novel Mutation in GATA4 Identified by Whole Exome Sequencing in a Family with Left Ventricular Noncompaction

1/2012-12/2013 University of Michigan Cardiovascular Center Inaugural Grant Fund Role: Co-Principal Investigator $35,000 Patient Specific Disease Models of Inherited Cardiomyopathies 2/2013-1/2015 University of Michigan Cardiovascular Center Inaugural Grant Fund Role: Co-Principal Investigator $50,000

Targeted Gene Editing in Hypertrophic Cardiomyopathy Using Transcription Activator-Like Effector Nucleases

1/2010-12/2012 University of Michigan Cardiovascular Center Inaugural Grant Fund Role: Principal Investigator $49,000

A Randomized Trial of Exercise Training in Hypertrophic Cardiomyopathy 6/2009-5/2012 University of Michigan Cardiovascular Center Inaugural Grant Fund Role: Principal Investigator $25,000

Molecular Phenotyping of Putative Genetic Modifiers in Arrhythmogenic Right Ventricular Cardiomyopathy

4/2010-3/2012 NIH 1P20 HL10148 Role: Site Principal Investigator (PI: Carolyn Ho, Brigham and Women’s Hospital)

Using Genetics for Early Phenotyping and Prevention of Hypertrophic Cardiomyopathy

6/2010-12/2011 University of Michigan, Michigan Institute for Clinical Health Research Role: Co-Principal Investigator (w/ Sara Saberi) $50,000 A Randomized Trial of Exercise Training in Hypertrophic Cardiomyopathy

6/2008-6/2011 University of Michigan Clinical Innovation Fund Role: Principal Investigator Hypertrophic Cardiomyopathy Program $2,723,000 (over 3 years) 4/2009-3/2011 NIH R21 HL089193-01A1 Role: Co-investigator (Margaret Westfall, PI) Protein expression in failing human hearts


4/2009-10/2009 University of Michigan, Innovations in Cardiovascular Medicine Grant

Principal Investigator $22,000 Consequences and Mechanisms of Ubiquitin Proteasome Dysfunction in Human Cardiomyopathies

7/2004-6/2009 American Heart Association Fellow to Faculty Transition Grant Principal Investigator Calcium-activated myofilament tension in cardiac contractile performance during acidosis

and ischemia Year 1: $65,000 (direct cost) Year 2-5: $132,000 (direct cost)

7/2006-6/2011 NIH R01 HL 59301 Role: Co-investigator (Joseph Metzger, PI) Troponin and Heart Function in Health and Disease $250,000 7/2006-6/2011 NIH R01 HL 71016 Role: Co-investigator (Joseph Metzger, PI) Genetic engineering of heart performance

$250,000

5/2003-6/2005 University of Michigan Cardiovascular Center McKay Grant Role: Principal Investigator Genetic Engineering of Calcium Handling and Diastolic Performance After Myocardial Infarction $25,000

7/2000-6/2004 NIH T32 Training Grant in Molecular and Cellular Cardiology, c) Submitted Grants

None Honors and Awards

1998 House Officer Research Award 1998 Bruce A. Jones Award for Outstanding House Staff Spirit 1999 Wyeth-Ayerst Women in Cardiology Travel Grant 2003 Winner, Young Investigator Award in Thrombosis; Arteriosclerosis, Thrombosis and Vascular

Biology Council of the American Heart Association. 2006 Cardiovascular Center Bridges in Science Award 2008 Winner, Outstanding Early-Career Investigator Award, Basic Science Council of the American

Heart Association 2011 Finalist, Early Independent Career Research Competition, Keystone Symposia on Molecular

Cardiology: Disease Mechanisms and Experimental Therapeutics 2014 Clinician of the Year, Hypertrophic Cardiomyopathy Association


2014-present Taubman Scholar, A. Alfred Taubman Medical Research Institute 2015-2017 Liz and Eric Lefkofsky Scholar 2015 Token of Appreciation from Medical Students Award

Membership in Professional Societies 2002-present American Heart Association 2011-present American College of Physicians Editorial Positions, Boards, and Peer-Review Service

Institutional 2004-present University of Michigan Cardiovascular Center McKay Grant Review Committee. 2016-2019 Biomedical Research Council National 2012-2014 Peer Review Committee, American Heart Association, Basic Cell – Proteins and

Crystallography Study Section 2012-present Sarnoff Cardiovascular Research Foundation Scientific Committee 2014-2015 Sarnoff Scientific Meeting Program Planning Committee 2014 Ad hoc reviewer, NIH/NHLBI Cardiac Contractility, Hypertrophy, and Failure Study Section 2015-2016 Co-chair, American Heart Association, Basic Cell – Proteins and Crystallography Study

Section 2016-present Sarnoff Foundation Nominating Committee for the Scientific Committee 2016-present Reviewer, VA Merit Review Cardiology A (CARA) Panel 2016 Reviewer, Special Emphasis Panel NIH/NHLBI ZRG1 CVRS-C (02) 2017-2018 Chair, American Heart Association, Basic Cell – Proteins and Crystallography Study Section 2017 Reviewer, Special Emphasis Panel NIH/NHLBI CVRS Ad hoc peer reviewer: Institutional 2006 Translational Research Initiative Grant 2006 Biomedical Research Council Bridging Support Program for Basic Science Research Grant 2008 Pilot Rare Diseases Initiative Grant 2008 Innovations in Cardiovascular Medicine Grant 2008 MICHR/CTSA Pilot and Collaborative Grant 2010 Biomedical Research Council Bridging Support Program for Basic Science Research Grant 2012 MICHR Pilot Grant Program Reviewer National/International Journals: 2003 Blood Coagulation and Fibrinolysis 2004 Academic Emergency Medicine 2004-2014 Circulation 2004-present Journal of the American College of Cardiology


2005 Metabolism 2006 Thrombosis and Haemostasis 2006-2009 American Heart Journal 2007 Journal of Molecular Medicine 2008 Life Sciences 2010-2011 Sports Health: A Multidisciplinary Approach 2009,2012 Circulation: Heart Failure 2009-2011 Annals of Internal Medicine: acknowledged as a top 10% reviewer in 2009 2009 Journal of Cardiovascular Translational Research 2009,2012 American Journal of Cardiology 2010 American Journal of Physiology: Heart and Circulatory Physiology 2010 FASEB Journal 2010-present New England Journal of Medicine 2010-present Journal of Molecular and Cellular Cardiology 2010 British Journal of Pharmacology 2011 Clinical Genetics 2011-present European Heart Journal 2011 European Journal of Heart Failure 2011-present Circulation: Cardiovascular Genetics 2012,2013 Circulation Research 2012 European Journal of Clinical Investigation 2012-present International Journal of Cardiology 2013-present PLOS One 2013 Cardiovascular Research 2014 Science Translational Medicine 2015 Proceedings of the National Academy of Sciences 2015 Journal of Medical Genetics 2016-present Journal of the American Heart Association Funding agencies 2015 The Netherlands Organisation for Health Research and Development, Veni Programme

Teaching Mentoring Year Trainee Project Position 2006-2013 Sarah Bartolone, BS Post-translational UPS regulation Applying MD/PhD 2007-2010 Frank Davis, BS HCM, sarcomere gene expression Medical student, UMich 2008-2010 Natalie Homer, BS HCM mutations and UPS function Medical student, N.western 2009-2011 David Coleman, BS HCM, sarcomere gene expression Medical student, Wayne St 2006-2009 Tamir Baman, MD Continuity and HCM clinics Private practice cardiologist 2008-2009 Renuka Jain, MD Aortic dilation and HCM Faculty, U of Minnesota 2008-2010 Elizabeth Reineck, MD Lifestyle practices in HCM CVM fellow, Penn State U 2009-2010 Sara Saberi, MD Exercise training in HCM Faculty, UMich 2009-2012 Anubhav Garg, MD Continuity/HCM clinics Private practice cardiologist 2009-2011 Brice Rolston, BS Exercise in HCM, Epi of SCD Medical student, UMich


2010-2012 Katherine Douglas, MD Ca handling in HCM CVM fellow, U Colorado 2011 Amanda Johnson, BS Post-translational UPS regulation Medical student, UMN 2011-2013 Suwen Kumar, MD Exercise in HCM Internal Medicine resident 2011-present Adam Helms, MD Stem cell models of HCM Faculty member, UMich 2011-2012 Brittany Batte, MS Family communication in HCM Genetic counselor 2011-2012 Kristin Bland Post-translational UPS regulation UROP 2012-2013 Mark Benson, MD SUMO modifications in heart failure CVM fellowship, Brigham 2012-2013 Benjamin Ebner . MD Obstructive sleep apnea in HCM CVM fellowship, Beaumont 2012 Natalie Ortiz Post-translational UPS regulation SURP summer fellowship 2012-2016 Vi Tang Gene editing in HCM CVC summer fellowship MYBPC3 HCM mutations AHA undergrad grant 2012-2013 Sourav Podder In vitro models of MYBPC3 HCM UROP 2013-2014 Brittany Batte Family communication in HCM Genetic counseling student 2013-present Amelia Glazier Chaperone activity in HCM Graduate student thesis 2013 Kristin Hsieh Immunoproteasomes in MI CVC summer fellowship 2014 Megan Ludwig Immunoproteasomes in MI Graduate student rotation 2014 Melanie Worley MYBPC3 mutation in HCM CVC summer fellowship 2014 Guillermo Moreno GATA4 mutations in LV noncompaction SURP summer fellowship 2014 Jordan Maxey Immunoproteasome in MI Medical student fellowship 2014-2015 Adam Fawaz Immunoproteasome in MI Master’s student, MIP 2014-2015 Bavica Gummadi Human stem cell models of HCM UROP 2014-2015 Lauren Hipp Genotype risk score in HCM Genetic counseling student 2014-present Mick Wauchope Human stem cell models of HCM UROP, SURF, SURP fellow 2015,2016 Srisha Kotlo Proteostasis in MYBPC3 HCM SURF, CVC summer fellow 2015 Eric Chang Interacting proteins with MYBPC3 CVC summer fellowship 2015-present Neha Hafeez HCM cellular and organ phenotypes Undergrad honor’s thesis 2015 Thomas Vigil Hsc70 substrates in cardiac myocytes Graduate student rotation 2016 Samantha Devenport Unfolded protein response in HCM Graduate student rotation 2015-present Akul Arora Immunoproteasome in MI UROP 2016-present Jonathan Herrera Exercise in HCM , cardiac aging MSTP student thesis 2016-present Eric Kersjes Noncompaction in HCM Medical student fellowship 2016-present Sean Luzon Cardiac aging SURF summer fellow 2016-present Ryan Mcgrath Abnormal exercise BP in HCM Resident research project 2016-present Eric Smith iPSC-myocyte HCM disease models Resident research project 2016-2017 Aaron Wasserman Truncated MYBPC3 in HCM Master’s student, MIP Intramural presentations/teaching 1999 Cardiology Joint Grand Rounds, UMich/St. Joseph Mercy Hospital, “Constrictive Pericarditis” 2000-2004 Instructor, M2 Introduction to the patient 2000-2006 Small group discussion leader, M1 and M2 Cardiology sections 2002 Hemostasis and Thrombosis Seminar, “Blood-borne Tissue Factor: Does it Participate in the

Thrombotic Response to Arterial Injury?” 2003 Organizer, M1 Multidisciplinary conference 2003-2005 Undergraduate Physiology Course, “Introduction to Cardiac Pathophysiology” 2004-present Attending physician, Cardiology Consultation, Inpatient Services and Outpatient General

Cardiology Clinics 2004-present Career Seminar Series, 1st and 2nd year medical students 2004 Neurosurgery Resident Teaching Conference, “Myocardial Infarction in Surgical Patients”,


2005 Cardiology Grand Rounds, “Troponin: The Chest Pain Center and Beyond” 2005 Cardiology Fellows’ Basic Science Teaching Conference, “Animal Models of Human Heart

Disease” 2006-2008 Clinical case series for Internal Medicine 3rd year medical student clerkship 2006 Internal Medicine Noon Conference, “Diagnosis and Management of Hypertrophic

Cardiomyopathy” 2007 Cardiology Content Expert, ENCORE Medical Student Education Program 2007 Internal Medicine Research Conference, “Sarcomere proteins in cardiac disease: from

mutations to genetic engineering” 2007 Cardiology Grand Rounds, “Update on Hypertrophic Cardiomyopathy and Early Clinic

Experience at Michigan” 2007-present Internal Medicine Resident Morning Report, 3-5 occasions per year 2007-present HG650/651 Advanced Clinical Concepts in Medical Genetics, “Cardiovascular Genetics”, 2008 Heart Failure Series for Nurse Practitioners, “Hypertrophic Cardiomyopathy” 2008 Department of Internal Medicine Grand Rounds, “Genetics of Hypertrophic

Cardiomyopathy” 2008 CME and Patient Education Course, Hypertrophic Cardiomyopathy Update, “Hypertrophic

Cardiomyopathy: An overview”, 2008 National Conference of State Legislators, “Genetics and the Heart”, 2009-2011 Monthly Cardiology Resident’s Rotation Lecture Series, “Hypertrophic Cardiomyopathy” 2009-2013 Electrophysiology Fellow’s Conference, annual presentation on “Molecular Aspects and

Genetics of Hypertrophic Cardiomyopathy” 2009 Frank N. Wilson Cardiovascular Medicine Society Faculty Presentation, “Present and Future

Clinical Applications of Cardiovascular Genetics” 2010 Cardiovascular Medicine Grand Rounds, “HCM potpourri for $500” 2010 Frontiers in Cardiovascular Science Seminar Series, “Protein Turnover in Human

Cardiomyopathies” 2011 Cardiovascular Medicine Grand Rounds, “Case Studies in Cardiovascular Genetic Testing” 2011 Medsport annual conference for athletic trainers, “The Heart of the Athlete: sudden death,

cardiovascular screening and preparedness” 2012 Department of Human Genetics Seminar Series, “Sarcomere Gene Mutations in

Hypertrophic Cardiomyopathy: Getting to the (Human) Heart of the Matter 2012 Pediatric Emergency Medicine Fellowship Lecture Series, “Cardiac Disease in Adolescence” 2013 Department of Internal Medicine Grand Rounds, “Insights into Hypertrophic

Cardiomyopathy Using Genetics, Proteomics, and Human Stem Cell-Derived Cardiac Myocytes”

2013 Preventive Cardiology, Hypertension, Vascular Medicine, Lipids/Atherosclerosis Conference, “Hypertrophic Cardiomyopathy”

2013 Department of Kinesiology, Advanced Cardiovascular Exercise Physiology, “Sudden Cardiac Death in the Young”

2014 Department of Molecular and Integrative Physiology Conference, “Dysregulation of Proteostasis in the Cardiomyopathic Heart”

2014 “Hypertrophic Cardiomyopathy: Diagnosis, Management and Genetics”, Take Heart: Update in Cardiovascular Nursing Symposium

2015 “The Cardiac Sarcomere: From Development to Disease”, Center for Organogenesis Cross Talk Seminar Series (with Mark Russell)

2015-present “Cardiomyopathies”, Physiology 600: Human Pathophysiology, Molecular and Integrative Physiology Master’s level course


2015-present “Cardiomyopathies”, Physiology 610: Translational Physiology, Molecular and Integrative Physiology Master’s level course

2015 “Sudden Cardiac Death Syndromes”, EP fellow’s conference 2015-2016 “The Balancing Act of a Physician Scientist”, Summer Undergraduate Research Fellowship

lecture series 2015 “Advances in Research: Current and Future Opportunities”, Affairs of the Heart: Living with

Genetic Cardiomyopathy, Patient Educational Conference 2015 “Finding a Niche as a Physician Scientist”, MSTP student seminar 2015 “Physician Scientist Career Choices”, First Year Medical Student Workshop 2016 “Hypertrophic Cardiomyopathy”, Internal Medicine Resident Noon Conference 2016 “Controversies in Screening and Sports Participation in Athletes with Inherited Cardiac

Disease”, Cardiovascular Medicine Grand Rounds 2016 “Hypertrophic Cardiomyopathy”, MidMichigan Health Seminar 2016 “HCM and Cardiac MRI”, Cardiovascular Radiology noon conference 2016 “Cardiomyopathy as a Protein Folding Disease”, Protein Folding Diseases Initiative Annual

Symposium Committee, Organizational, and Volunteer Service: Institutional

1996-1998 House Officer Council 2001 Organizer, Cardiovascular Research Center Spring Symposium 2002-present Cardiology Fellowship Selection Committee 2004 Selection committee, Huetwell Professorship in Hypertension or Vascular Medicine 2004-present Internal Medicine House Officer Interviews for the Physician Scientist Program 2005-present GMEC Committee for Cardiology Fellowship Program 2007 Galen’s Medical Society “Happy Van” driver 2008 CME and Patient Education Course Director “Hypertrophic Cardiomyopathy Update” 2009-2010 Molecular and Integrative Physiology Endowed Chair Search Committee 2010-present Faculty member, Center for Organogenesis 2010-present Center for Organogenesis Steering Committee 2010-present Center for Organogenesis Seminar Committee 2010-present Nepotism Committee for the Department of Internal Medicine 2011 Organizer for symposium on “Sudden Cardiac Arrest in Students and Student Athletes” 2011-2012 Pulmonary Medicine Internal Review Committee for the Department of Internal Medicine 2012 Organizer for symposium on “Sudden Cardiac Arrest in Students: Screening and

Preparedness for Healthcare Providers”

2012-2013 Cardiovascular Team/Section Co-Leader for the University of Michigan Medical School FastForward Personalized Medicine Initiative

2012-present Executive Committee Member, Protein Folding Diseases Section for the University of Michigan Medical School FastForward Personalized Medicine Initiative

2012-2013 Search committee, Endowed Chair of Cardiovascular Physiology, Department of Molecular and Integrative Physiology

2013-2014 Graduate Student Preliminary Examination Committee, Department of Molecular and Integrative Physiology, Francisco Alvarez (Mentor: Hector Valdivia).

2014-present Graduate Student Dissertation Committee, Department of Molecular and Integrative Physiology, Francisco Alvarez (Mentor: Hector Valdivia)


2014-2015 Graduate Student Preliminary Examination Committee, Department of Cellular and Molecular Biology, Brittany Flores (Mentor: Sami Barmada)

2015-present Department of Internal Medicine CV Review and Promotions Committee 2015-present Molecular and Integrative Physiology Graduate Committee 2015-2016 Graduate Student Preliminary Examination Committee, Department of Pathology, Samir

Nath (Mentor: Andrew Lieberman) 2016 Faculty Lead, Patient-Based Scientific Inquiry, 4th year Medical Students 2016-present Graduate Student Dissertation Committee, Department of Pathology, Samir Nath (Mentor:

Andrew Lieberman) 2016-2019 Biomedical Research Council (BMRC) Regional 2007-2009 Sudden Cardiac Death Mortality Advisory Panel for the Michigan Department of Community

Health 2008 “Provider Education and Public Awareness of Sudden Cardiac Death in the Young Risk

Factors”, Action team leader, Sudden Cardiac Death in the Young in Michigan: Call to Action, Lansing, MI

2012-present Sudden Cardiac Death in the Young Advisory Council Visiting Professorships, Seminars, and Extramural Invited Presentations:

Seminars and invited presentations 2004 Oakwood Hospital, Dearborn, MI, “Hypertrophic cardiomyopathy; what the practicing

internist needs to know” 2006 Cardiology Grand Rounds, University of Missouri, Columbia, MO, “Troponin: Something old,

something new” 2006 Fall CME program, Penn State University, PA, “Recognition and Management of

Hypertrophic Cardiomyopathy” 2007 Hypertrophic Cardiomyopathy Association Annual Meeting, Morristown, NJ, “Introduction

to the University of Michigan Hypertrophic Cardiomyopathy Program” 2007 Cardiology Update, CME program, Mackinac Island, MI, “Genetic Cardiovascular Diseases”,

“Diagnosis and Management of Hypertrophic Cardiomyopathy” 2008 Hypertrophic Cardiomyopathy Association Annual Meeting, Morristown, NJ, “Exercise and

Hypertrophic Cardiomyopathy” 2008 American College of Osteopathic Internists 68th Annual Convention and Scientific Sessions,

“Hypertrophic Cardiomyopathy: What’s important to know and is genetic testing ready for primetime?”

2009 Michigan Osteopathic Association, 110th Annual Postgraduate Convention and Scientific Seminar, “Hypertrophic Cardiomyopathy”,

2009 Hypertrophic Cardiomyopathy Association Annual Meeting, Morristown, NJ, “Medical Management of Hypertrophic Cardiomyopathy” “Exercise with Hypertrophic Cardiomyopathy”

2009 Athlete’s Heart, Sudden Death and Hypertrophic Cardiomyopathy Conference, Stanford University: “Living with Hypertrophic Cardiomyopathy” (patient panel) “Role of Stress Testing in Hypertrophic Cardiomyopathy” “Medical Therapy and Exercise in Hypertrophic Cardiomyopathy”


2009 Molecular and Integrative Physiology Seminar, University of Minnesota, “Regulation of Proteasome Function in Cardiomyopathies”

2010 Michigan Department of Community Health Educational Video Series, “Hypertrophic Cardiomyopathy: A Major Cause of Sudden Cardiac Death in the Young”

2010 Oakwood Southshore Hospital Grand Rounds, “Genetics of Inherited Cardiomyopathies” 2010 Advances in Forensic Medicine and Pathology, University of Michigan Department of

Pathology, CME program, “Molecular Diagnostics of Cardiac Disease” 2010 Hypertrophic Cardiomyopathy Association Annual Meeting, Morristown, NJ

“Medical Management of Hypertrophic Cardiomyopathy” “Exercise with Hypertrophic Cardiomyopathy”:

2010 Heart and Art: An Update on Common Cardiovascular Disorders, University of Michigan Cardiovascular Center CME program, “LVH on Echo: When Should I Be Worried?

2010 Hartford Hospitals 26th Annual Cardiovascular Symposium, “Inherited Cardiomyopathies” 2010 University of Chicago Cardiovascular Medicine Grand Rounds, “Hypertrophic

Cardiomyopathy: From Sarcomere Biology to Clinical Practice” 2011 Keynote address, American Heart Association Celebration of Science, “Hypertrophic

Cardiomyopathy: From Observation to Intervention” 2011 University of Manchester Research Seminar, Manchester, England, “Sarcomere Gene and

Protein Expression Studies Suggest Mutation-Specific Disease Mechanisms in Human Hypertrophic Cardiomyopathy”

2011 Hypertrophic Cardiomyopathy Association Annual Meeting, Morristown, NJ, “Medical Management of Hypertrophic Cardiomyopathy and How to Counsel Patients on Exercise”

2011 Symposium on Sudden Cardiac Arrest in Students and Student Athletes, University of Michigan CME program, Ann Arbor, MI, “Prevalence and Causes of Sudden Cardiac Arrest in the Young”

2011 Promedica’s Continuing Education Program and Northwest Ohio Cardiology Consultants, Symposium on Sudden Cardiac Arrest, Perrysburg, Ohio, “Sudden Cardiac Death in Youth”

2012 Heart Rhythm Society Annual Meeting, Boston, MA, “How to Approach Genetic Testing for Sudden Cardiac Death/ When and How to Organize DNA Banking for a Family”

2012 Symposium on Sudden Cardiac Arrest in Students: Screening and Preparedness for Health Care Providers, University of Michigan CME program, “Epidemiology of Sudden Cardiac Arrest and Inherited Cardiomyopathies”

2012 Hypertrophic Cardiomyopathy Association Annual Meeting, Morristown, NJ, “Lifestyle, Career choices and Pregnancy in HCM”

2012 Cardiovascular Medicine Grand Rounds, University of Illinois, Chicago, IL, “In Search of Genotype-Phenotype Correlations in Hypertrophic Cardiomyopathy”

2012 Alma College Integrated Health Studies Institute Annual Health Symposium, Alma, MI, “Hypertrophic Cardiomyopathy: Risks, Management, and Exercise Recommendations”

2013 Albert Einstein College of Medicine Research Seminar Series, “Potential Approaches to Better Understand and Treat Hypertrophic Cardiomyopathy”

2013 American College of Cardiology Annual Meeting, San Francisco, CA, “Exercise Training in Patients with Hypertrophic Cardiomyopathy”

2013 Heart Rhythm Society Annual Meeting Denver, CO, “Risk of Sports-Related Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy”

2013 Cardiology Update, CME Program, Mackinac Island, MI, “Cardiovascular Genetics”, “The Vagaries of LVH”, “Case Studies of the Cardiomyopathies: HCM, Noncompaction”

2013 American Heart Association Annual Meeting, Dallas, TX, “Genetic testing: Interpretation and Counseling”


2013 American Heart Association Annual Meeting, Dallas, TX. Moderator, “Dynamics of Protein Degradation Machinery in Cardiac Function”

2013 American Heart Association Annual Meeting, Dallas, TX. Panelist, “Management of Hypertrophic Cardiomyopathy: A Heart Team Approach Case Theater”

2014 36TH Annual Big Sky Cardiology, Big Sky Montana. “Hypertrophic cardiomyopathy today: Diagnosis and Genetic Testing, Current Therapies”; “How should we screen athletes?”

2014 Update on Advanced Cardiac Imaging, Ann Arbor, MI. “How Should We Evaluate Suspected Hypertrophic Cardiomyopathy”

2014 West Virginia University, Morgantown, WV, Biochemistry Research Forum. “Overwhelmed, Disassembled and Maladapted: Ubiquitin Proteasome Dysfunction in Cardiomyopathies”

2014 West Virginia University, Morgantown, WV, Cardiovascular Disease Grand Rounds, “Hypertrophic Cardiomyopathy: From Observation to Intervention”

2014 Shanty Creek CME Conference (50th Anniversary), “Controversies in Athlete Screening”; “Genetics in your Practice: The Revolution is Upon Us”

2014 University of Michigan, Protein Folding Diseases Fall Symposium, “Hypertrophic Cardiomyopathy as a Protein Folding Disease”

2014 University of Vermont, Burlington, VT, Research seminar, “Hypertrophic Cardiomyopathy Associated with Mutations in Myosin Binding Protein C: Haploinsufficiency or Poison Peptide?”

2014 American Heart Association Annual Meeting, Chicago, IL. “Exercise in HCM: How much and how hard?”

2014 American Heart Association Annual Meeting, Chicago, IL., “Genetic Testing: Interpretation and Counseling”

2015 American College of Cardiology Annual Meeting, San Diego, CA., “Can Athletes with HCM Compete?”

2015 University of Arizona, Tucson, AZ, Research seminar, “Hypertrophic Cardiomyopathy Associated with Mutations in Myosin Binding Protein C: Haploinsufficiency or Poison Peptide?”

2015 American Heart Association Annual Meeting, Orlando, FL., “Sarcomere gene expression” 2015 American Heart Association Annual Meeting, Orlando, FL., “Exercise in HCM: How Much

and How Hard?” 2016 Rio De Janeiro 2016: Sociedade de Cardiologia do Estado do Rio de Janeiro/American

College of Cardiology. Annual Meeting, Rio de Janeiro, Brazil. “Sports and Exercise for Patients with Hypertrophic Cardiomyopathy and Arrhythmogenic Right Ventricular Dysplasia”; “Sports and Exercise for Patients with Implantable Cardioverter Defibrillators and Pacemakers”

2016 CARDIA: Cardiac Arrhythmias, Sudden Death, Inherited Disease, Athletes. A CME conference sponsored by Stanford University. “Exercise and Inherited Disease”

2016 Northwestern University Feinberg Cardiovascular Research Institute, Monthly Molecular Cardiology Research Conference, scheduled, “Is Hypertrophic Cardiomyopathy a Protein Folding Disease?”

2016 Weill Cornell Medicine, Cardiovascular Medicine Grand Rounds, “Hypertrophic Cardiomyopathy: Facts or Fiction?”

2016 American Heart Association Annual Meeting, New Orleans, “Exercise in HCM: Good or Bad?”

2017 Case Western Reserve University, Department of Physiology and Biophysics Seminar Series, Title TBD

2017 American College of Cardiology Annual Meeting, Washington DC, “Athletes and Cardiomyopathy”


Patents Compositions and Methods for Regulating Cardiac Performance PCT/US2005/043584 USPTO Patent Number: 8,557,969

UM Tech Transfer File Number: 2904 Bibliography: Peer-reviewed Journals and Publications 1. Day SM, Rosenzweig BP, Kronzon I. Transesophageal Echocardiographic Diagnosis of Right Atrial Thrombi

Associated With the Antiphospholipid Syndrome. J Am Soc Echocardiography 1995, 8: 937-940. 2. Sticherling C, Day SM, Michaud GF. Complete Heart Block Associated with Cardiac Arrest During Oral

Amiodarone Loading Therapy. Heart Web, Aug 1999; 4(10);99100005. 3. Day SM, Younger JG, Karavite D, Bach DS, Armstrong WF, Eagle KA. Usefulness of Hypotension During

Dobutamine Echocardiography in Predicting Perioperative Cardiac Events. Am J Cardiology 2000, 85(4):478-483.

4. Day SM, Duquaine D, Rajagopalan S, Mundada LV, Menon RG, Khan BV, Fay WP. Chronic Iron Administration Increases Vascular Oxidant Stress and Accelerates Thrombosis in Response to Arterial Injury. Circulation 2003, 107: 2601-2606.

5. Coutu P, Bennett CN, Favre EG, Day SM, Metzger JM. Parvalbumin Corrects Slowed Relaxation in Adult

Cardiac Myocytes Expressing Hypertrophic Cardiomyopathy-Linked -Tropomyosin Mutations. Circ Research 2004; 94:1235-1241.

6. Day SM, Fay WP. Murine Thrombosis Models. Thrombosis and Haemostasis 2004; 92:486-494. 7. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, Wakefield TW, Mackman N, Fay WP.

Macrovascular Thrombosis is Driven by Tissue Factor Derived Primarily from the Blood Vessel Wall. Blood 2005; 105:192-198.

8. Yasuda S*, Townsend D*, Favre E, Michele D, Day SM, Metzger J. Dystrophic Heart Failure Blocked by Membrane Sealant Poloxamer. *Co-first authors. Nature 2005; 436:1025-1029.

9. Day SM*, Westfall MV*, Fomicheva K, La Cross N, Yasuda S, Metzger JM. Histidine Button Engineered into Cardiac Troponin I Protects the Heart from Ischemia and Heart Failure. *Co-first authors. Nature Medicine 2006; 12:181-189.

10. Tilley RE, Pedersen B, Sato Y, Shen Y, Day SM, Eitzman DT, Curtiss LK, Fay WP, Boisvert W, Mackman N. Atherosclerosis in Mice is not Affected by a Reduction in Tissue Factor Expression. Arteriosclerosis Thrombosis and Vascular Biology 2006; 26:555-562.

11. Day SM, Davis J, Westfall MV, Metzger JM. Genetic Engineering and Therapy for Inherited and Acquired Cardiomyopathies. The Annals of the New York Academy of Science 2006; 1080:437-450.

12. Day SM, Westfall MV, Metzger JM. Tuning Cardiac Performance in Ischemic Heart Disease and Failure by Modulating Myofilament Function. J Mol Med 2007, 85:911-921.

13. Chang L, Zhang J, Tseng Y, Xie C, Ilany J, Bruning J, Sun Z, Zhu X, Cui T, Youker KA, Yang Q, Day SM, Kahn R, Chen E. Rad GTPase deficiency leads to cardiac hypertrophy. Circulation 2007; 116:2976-2983.

14. Day SM, Coutu P, Wang W, Herron T, Turner I, Shillingford M, La Cross N, Converso KL, Piao L, Li J, Lopatin AN, Metzger JM. Cardiac-Directed Parvalbumin Expression Shows Marked Heart Rate-Dependence of Delayed Ca2+ Buffering Action. Physiological Genomics 2008; 33:312-322.

15. Palpant N, Day SM, Herron TJ, Converso KL, Metzger JM. Single Histidine Substituted Cardiac Troponin I Confers Protection from Age-related Systolic and Diastolic Dysfunction. Cardiovascular Research 2008;


80:209-218. (Performed experiments, data analysis and interpretation, and contributed to manuscript preparation).

16. Attili A, Mueller GC, Day SM. Asymptomatic Man with Giant Negative T Waves on ECG. American Journal of Roentgenology 2009; 192(3Suppl):S57-62.

17. Day SM. Exercise in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Translational Research 2009; 2:407-414.

18. Gupta S, Baman T, Day SM. Cardiovascular Health – Part One: Pre-participation Cardiovascular Screening. Sports Health: A Multidisciplinary Approach 2009; 1:500-507.

19. Baman T, Gupta S, Day SM. Cardiovascular Health – Part Two: Sports Participation in Athletes with Cardiovascular Conditions. Sports Health: A Multidisciplinary Approach 2010; 2:19-28.

20. Herron TJ, Devaney E, Mundada L, Arden E, Day SM, Guerrero-Serna G, Turner I, Westfall MW, Metzger JM.

Calcium-independent positive molecular inotropy for failing rabbit and human cardiac muscle by -myosin motor gene transfer. FASEB Journal 2010; 24:415-4224. (Contributed to experimental design, data interpretation and manuscript preparation).

21. Predmore JL, Wang P, Davis FR, Bartolone S, Westfall MV, Pagani F, Dyke DB, Powell SR, Day SM. Ubiquitin Proteasome Dysfunction in Human Hypertrophic and Dilated Cardiomyopathies. Circulation 2010;121:997-1004.

22. Brown C, Day SM, Rehm HL, Baxter S. Use and Interpretation of Genetic Tests in Cardiovascular Genetics. Heart 2010;96:1669-1675. (Contributed content to manuscript preparation).

23. Day SM, Thompson PD. Cardiac Risks Associated with Marathon Running. Sports Health: A Multidisciplinary Approach 2010;2:301-306.

24. Aatre R, Day SM. Psychological Issues in Cardiovascular Genetic Testing. Circulation: Cardiovascular Genetics 2011;4:81-90.

25. Stein AB, Jones TA, Herron TJ, Patel SR, Day SM, Dressler GR. A Role for H3K4 Methylation in Stabilizing Gene Expression Patterns and Physiological Functions in Adult Cardiomyocytes. J Clin Invest 2011;121(7):2641-50. (Performed experiments, critically reviewed data interpretation and manuscript).

26. Day SM. Anxiety in Patients with ICDs and Arrhythmogenic Right Ventricular Cardiomyopathy. Invited editorial. Circulation: Cardiovascular Genetics 2012;5:2-4.

27. Koenig GC, Rowe RG, Day SM, Sabeh F, Atkinson JJ, Cooke KR, Weiss SJ. MT-MMP-Dependent Remodeling of Cardiac Extracellular Matrix Structure and Function Following Myocardial Infarction. American Journal of Pathology 2012;180(5):1863-78. (Performed experiments, data interpretation, manuscript preparation)

28. Hwang H, Robinson DA, Stevenson TK, Wu HC, Kampert SE, Pagani FD, Dyke DB, Martin JL, Sadayappan S,

Day SM, Westfall MV. PKCII Modulation of Myocyte Contractile Performance. J Mol Cell Cardiol 2012;53:176-186. (Performed experiments, critically reviewed manuscript)

29. Svoboda LK, Reddie KG, Zhang L, Vesely ED, Williams ES, O’Connell RP, Day SM, Anumonwo JM, Carroll KS, Martens JR. A Redox-sensitive Fate Switch Controls Ion Channel Surface Density and Degradation. Circ Research 2012;111:842-853. (Designed and performed experiments, critically reviewed manuscript)

30. Cotts T, Rogers FJ, Mueller G, Day SM. Coronary Artery Thromboembolism as a Result of Left Ventricular Sump Aneurysm after Congenital Heart Surgery. J Thor Cardiovasc Surgery 2012;144:e119-121.

31. Reineck E*, Rolston B*, Bragg-Gresham J, Salberg L, Baty LC, Kumar S, Wheeler M, Ashley E, Saberi S, Day SM. Physical Activity and Other Health Behaviors in Adults With Hypertrophic Cardiomyopathy. Am J Cardiol 2013;111:1034-1039.

32. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA Mark, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Berger SN, Maron MS, and Link MS. Prevention of Sudden Cardiac Death with the Implantable Cardioverter-Defibrillator in Children and Adolescents with Hypertrophic Cardiomyopathy. J Am Coll Cardiol 2013;61:1527-35. (Provided and interpreted data, critical review of the manuscript)


33. Day SM, Divald A, Wang P, Davis FR, Bartolone S, Jones R, Powell SR. Impaired Assembly and Post-translation Regulation of 26S Proteasome in Human End Stage Heart Failure. Circ: Heart Failure 2013;6:544-549.

34. Day SM. The Ubiquitin Proteasome System in Human Cardiomyopathies and Heart Failure. Am J Physiol: Heart Circ Physiol 2013;304:H1283-H1293.

35. Kamp AN, Von Bergen NH, Henrikson CA, Makhoul M, Saarel EV, OaPage MJ, Russell MW, Strieper M, Yu S, Dick M, Day SM, Bradley DJ. Implanted Defibrillators in Young Hypertrophic Cardiomyopathy Patients: A Multicenter Study, Pediatric Cardiology 2013;34(7):1620-1627. (Provided and interpreted data, critical review of the manuscript)

36. Hwang H, Robinson D, Stevenson T, Rogers J, Kampert S, Sadayappan S, Day SM, Sivaramakrishnan S,

Westfall MV. Agonist Activated PKCII Translocation and Modulation of Cardiac Myocyte Contractile Function. Scientific Reports 2013;3:1971.(Data analysis, critical review of the manuscript).

37. Jain R, Helms A, Day SM, Booher AM. Prevalence of aortic dilation in hypertrophic cardiomyopathy. Am J Cardiovasc Dis 2013;3(2): pages 79-84.

38. Puckelwartz MJ, Pesce L, Dewey F, Nelakuditi V, Dellefave-Castillo L, Golbus JR, Day SM, Cappola T, Ashley E, Dorn, G, Foster I, McNally EM. Supercomputing for the Parallelization of Whole Genome Analysis. Bioinformatics 2014;30(11):1508-1513. (Provided data, critical review of the manuscript).

39. Helms AS*, Davis FR*, Coleman D, Bartolone S, Glazier A, Pagani F, Yob J, Sadayappan S, Pedersen E, Lyons R, Westfall MV, Jones R, Russell M, Day SM. Sarcomere Mutation-Specific Expression Patterns in Human Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics 2014;7:434-443.

40. Coppini R, Ho C, Ashley E, Day SM, Ferrantini C, Girolami F, Tomberli B, Bardi S, Torricelli F, Cecchi F, Poggesi C, Tardiff J, Olivotto I. Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated with Sarcomere Thin Filament Gene Mutations. J Am Coll Cardiol 2014;64(24):2589-2600. (Provided and interpreted data, critical review of the manuscript)

41. Captur G, Lopes LR, Mahun TJ, Patel V, Li C, Bassett P, Finocchiaro G, Ferreira VM, Esteban MT, Muthurangu V, Sherrid MV, Day SM, Canter CE, McKenna WJ, Seidman CE, Bluemke DA, Elliott PM, Ho CY, Moon JC. Prediction of Sarcomere Mutations in Subclinical Hypertrophic Cardiomyopathy. J Am Coll Cardiol: Cardiovascular Imaging 2014 Nov;7(6):863-871. (Provided and interpreted data, critical review of the manuscript).

42. McCarthy M, Procario MC, Twisselmann N, Wilkinson JE, Archambeau AJ, Michele D, Day SM, Weinberg J. Proinflammatory Effects of Interferon gamma in Mouse Adenovirus Type 1 Myocarditis. J Virology 2014;89(1):468-479. (Study design, data interpretation, critical review of manuscript)

43. Batte B, Sheldon J, Arscott P, Huismann D, Salberg L, Day SM, Yashar B. Family Communication in a Population at Risk for Hypertrophic Cardiomyopathy. J Genetic Counseling 2015;24:336-348. (Study design, data interpretation, critical review of the manuscript)

44. Alpert C, Day SM, Saberi S. Sports and Exercise in Athletes with Hypertrophic Cardiomyopathy. Clinics in Sports Medicine 2015;34(3):489-505.

45. Helms A, Day SM. Hypertrophic Cardiomyopathy: Single Gene Disease or Complex Trait? European Heart Journal 2016;Jun 14;37(23):1823-5.

46. Kim EH, Galchev VI, Kim JY, Misek SA, Stevenson TK, Campbell MD, Pagani FD, Day SM, Johnson TC, Washburn JG, Vikstrom KL, Michele DE, Misek DE, Westfall MV. Differential Protein Expression and Basal Lamina Remodeling in Human Heart Failure. Proteomics Clinical Applications 2016 May;10(5):585-96.

47. Homburger J, Green EM, Caleshu C, Sunitha M, Taylor R, Ruppel KM, Metpally R, SHaRe Investigators, Colan SD, Michels M, Day SM, Olivotto I, Bustamante CD, Dewey F, Ho C, Spudich JA, Ashley E. Multi-dimensional structure function relationship in human beta cardiac myosin from population scale genetic variation. Proceedings National Academy of Sciences, 2016; Jun 14;113(24):6701-6.

48. Rocha AM, Guerrero-Serna, Helms A, Mironov S, Russell MW, Jalife J, Day, SM, Smith GD*, Herron TJ*. Deficient cMyBP-C protein expression during early cardiac differentiation underlies human hypertrophic


cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes. *Co-corresponding authors. J Mol Cell Cardiol 2016 Sept 10;99:197-206

49. Kalbitz M, Fattahi F, Herron TJ, Grailer JJ, Jajou L, Lu H, Huber-Lang M, Zetoune FS, Sarma JV, Day SM, Russell MW, Jalife J, Ward PA. Complement Destabilizes Cardiomyocyte Function in Vivo after Polymicrobial Sepsis and in Vitro. J Immunol 2016 Sep 15;197(6):2353-61

50. Saberi S, Day SM. Exercise Prescription for the Athlete with Cardiomyopathy. Cardiol Clin 2016 Nov;34(4):591-601

51. McCarthy M, Malitz DH, Molloy CT, Procario MC, Greiner KE, Zhang L, Wang P, Day SM, Weinberg JB. Interferon-dependent Immunoproteasome Activity During Mouse Adenovirus Type I Infection. Virology 2016 Nov;498:57-68.

52. Helms AS, Alvarado F, Yob JM, Tang V, Bartolone S, Pagani F, Russell MW, Valdivia H, Day SM. Genotype Dependent Calcium Signaling Dysfunction in Human Hypertrophic Cardiomyopathy. Circulation 2016;134:1738-1748. Accompanying editorial, Circulation 2016;134:1749-1751

53. Lynch TL, Kuster DWD, Gonzalez B, Balasubramanian N, Nair N, Day SM, Calvino JE, Tan Y, Liebetrau C, Troidl C, Hamm CW, Guclu A, McDonough B, Marian AJ, van der Velden J, Seidman CE, Huggins GS, Sadayappan S. Cardiac Myosin Binding Protein-C Autoantibodies are Potential Early Indicators of Cardiac Dysfunction and Patient Outcomes in Acute Coronary Syndrome. JACC: Basic to Translational Science 2017, in press.

54. Helms AS, Day SM. Other Side of the Coin: Missing Heritability in Hypertrophic Cardiomyopathy. European Heart Journal 2017, in press.

55. Ho CY, Day SM, Colan SD, Russell MW, Towbin J, Sherrid M, Canter CE, Jeffries JL, Murphy A, Taylor M, Mestroni L, Cirino AL, Bluemke DA, Abraham TP, Jarolim P, Sleeper LA, Shi L, Seidman CE, Orav EJ for the HCM Net Investigators. The Burden of Early Phenotypes and the Impact of Left Ventricular Wall Thickness on Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers: Findings from the HCM Net Study. JAMA Cardiology 2017, in press.

56. Hipp LE, Arscott P, Concannon M. Yashar BM, Saberi S, Day SM. Family History as a Predictor of Mutation Positive Status in Hypertrophic Cardiomyopathy: Refining a Genotype Risk Algorithm. In revision

57. Powell SR, Wang P, Chatterjee P, Maxey J, Yob J, Weinberg J, Metz C, Day SM. Immunoproteasome Exacerbates Cardiac Remodeling in Ischemic Cardiomyopathy. In revision.

58. Ho CY, Cirino AL, Colan SD, Day SM, Desai A, Lipshultz SE, MacRae CA, McMurray JJV, Solomon SD, Shi L, Orav EJ, Braunwald E. Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy: The VANISH Trial Protocol. In revision, American Heart Journal.

59. Ho CY, Day, SM, Ashley EA, Michels M, Pereira A, Jacoby D, Fox J, Caleshu C, Cirino AL, Ware J, Helms AS, Colan SD, Signorovich J, Green E, Olivotto I. Examining Natural History and Genotype-Phenotype Correlations in Hypertrophic Cardiomyopathy: Findings from the Sarcomeric Human Cardiomyopathy Registry. Submitted.

Non Peer-Reviewed Publications 1. Day SM, Fay WP. Reply to rebuttal: Need for Mechanical Ventilation with Murine Thrombosis Models.

Thrombosis and Haemostasis 2005; 93:390. 2. Day SM, Mackman N, Fay WP. Invited response to letter to the editor: Role of Leukocyte- vs. Vascular-wall-

derived Tissue Factor in Murine Thrombosis. Blood 2005;106:1506-1507. Book Chapters 1. Kessler M, Saberi S, Day SM, Gay T, Baty L, Deneke E. Hypertrophic Cardiomyopathy (2011), in Psychiatry

and Heart Disease: the Mind, Brain, and Heart. Edited by Riba M, Wulsin L, Rubenfire M. Wiley-Blackwell, John Wiley & Sons, Ltd., West Sussex, UK, 2012:106-115.

Abstracts


1. Day SM, Younger JG, Karavite D, Bach DS, Armstrong WA, Eagle KA.. Prognostic Value of Dobutamine

Induced Arrhythmias in Perioperative Risk Stratification. Michigan Chapter of the American College of Physicians, 1997. Poster presentation.

2. Day SM. An Epicardial Abscess Associated with Bacterial Endocarditis.” Michigan Chapter of the American College of Cardiology Vignette Competition, 1997.

3. Lowell, M., Day SM. “Prevalence and Diagnostic Impact of Psychiatric Disorders in Chest Pain Center Patients. Academic Emergency Medicine, 1997.

4. McBryde N, Day SM. Nontraumatic Fat Embolism and Fungemia.” Michigan Chapter of the American College of Physicians, 1998, poster presentation.

7. Day SM, Younger JG, Karavite D, Bach DS, Armstrong WA, Eagle KA. The Role of Arrhythmias Induced During Dobutamine Echocardiography in Perioperative Risk Assessment. Michigan Chapter of the American College of Cardiology, 1998. Poster presentation.

8. Day SM, Younger JG, Karavite D, Bach DS, Armstrong WA, Eagle KA. The Role of Arrhythmias Induced During Dobutamine Echocardiography in Perioperative Risk Assessment: Do They Correlate with Postoperative Complications? University of Michigan Cardiology Research Symposium, 1998. Poster presentation.

7. Nath PA, Day SM, Poldermans D, Karavite D, Eagle KA, Sonnad SS. A Neural Network Model for Predicting Cardiac Risk Incorporating Clinical Risk Factors and Dobutamine Echocardiogram Results. Medical Decision Making 1998, 18(4): 456.

8. Day SM, Younger JG, Karavite D, Bach DS, Armstrong WA, Eagle KA. Hypotension During Dobutamine Echocardiography Predicts Perioperative Cardiac Events. J Invest Med 1999, 47(7) Suppl S: 221A.

9. Day SM, Younger JG, Karavite D, Bach DS, Armstrong WF, Eagle KA. Usefulness of Hypotension During Dobutamine Echocardiography in Predicting Perioperative Cardiac Events. J Am Coll Cardiol 2000, 35(2) Suppl A: 439A

10. Day SM, Fay, WP. Iron Accelerates Arterial Thrombosis in a Murine Carotid Injury Model”, Internal Medicine Research Day, 2001. Oral presentation.

11. Day SM, Fay, WP. Chronic Iron Administration Accelerates the Thrombotic Response to Arterial Injury.” Internal Medicine Research Day, 2002. Oral presentation.

12. Reeve JL, Day SM, Fay WP. The Thrombotic Response to Arterial Injury is Enhanced in Cathepsin S-Deficient Mice. Internal Medicine Research Day, 2002. Poster presentation.

13. Day SM, Fay, WP. Iron Loading Accelerates Arterial Thrombosis After Vascular Injury, Third Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology. Arterioscl Thromb Vas 2002, 22(5): P368.

14. Day SM, Reeve JL, Pedersen B, Mackman N, Fay WP. A Marked Reduction in Leukocyte Tissue Factor Does Not Impair Arterial Thrombosis in Mice. Circ 2002, 106(19) Suppl II: 192

15. Day SM, Reeve JL, Mundada L, Rottschafer H, Shi GP, Fay WP. Cathepsin S-deficient Mice Display a Prothrombotic Phenotype. Circ 2002, 106(19) Suppl II: 195.

16. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, Wakefield TW, Mackman N, Fay WP. Vessel Wall Tissue Factor Mediates Thrombosis Independently of Leukocyte Tissue Factor. Arterioscl Thromb Vas 2003, 23(5): 19.

17. Day SM, Reeve JL, Pedersen B, Farris DM, Myers DD, Im M, Wakefield TW, Mackman N, Fay WP. Vessel Wall Tissue Factor Mediates Thrombosis Independently of Leukocyte-Derived Tissue Factor. Internal Medicine Research Day, 2003. Poster presentation.

18. Reeve JL, Day SM, Fay WP. Quantitative Comparison of Circulating vs. Vascular Wall Tissue Factor Activity. Blood 2003, 102(11):2025.

19. Day SM, Fomicheva E, LaCross N, Westfall MV, Metzger JM. Expression of cTnI Mutant A164H Increases Myofilament Calcium Sensitivity and Improves Cardiac Performance During Acidosis”. Internal Medicine Research Day, 2004. Oral presentation.

20. Metzger JM, Fomicheva K, Fors C, Westfall MV, Day SM. Cardiac troponin I mutant A164H attenuates acidic pH-mediated myocyte force decline in transgenic mice. Biophysics 2004, 86(1) Part 2 Suppl S., 385A.


21. Day SM, Fomicheva E, LaCross N, Westfall MV, Metzger JM. Transgenic and gene transfer-based expression of cardiac troponin I mutant A164H increases myofilament calcium sensitivity under acidic conditions. Keystone Symposia, 2004. Plenary session oral presentation.

22. Westfall MV, Day SM, Robinson D. Protein kinase C alpha expression decreases adult cardiac myocyte contractile performance”. Keystone Symposia, 2004. Poster presentation.

23. Day SM, Westfall MV, Fomicheva K, LaCross N, Yasuda S, Favre E, Metzger JM. Preserved Myocardial Function During Acidosis and Ischemia by Transgenic Expression of Modified Troponin I. Circ 2004, 110(17) Suppl III:226.

24. Fomicheva E, Favre E, Day SM, Westfall MV, Davis J, Edwards T, Wen H, Metzger JM. Effect of stimulation rate on force generation in cardiac myocytes from transgenic mice with cardiac troponin I single histidine substitution on cTnI A164H. Biophysics 2005.

25. Tilley R, Pedersen B, Sato Y, Shen YC, Day SM, Eitzman D, Curtiss L, Fay W, Mackman N. Genetic Reduction of Tissue Factor Does Not Affect the Progression of Atherosclerosis in Mice. ATVB 2005.

26. Day SM, Westfall MV, Converso KL, Fomicheva E, Robinson D, Pagani F, Metzger JM. Cardiac troponin I substitution A164H acts as a molecular inotrope for the cardiomyopathic rodent heart and failing human cardiac myocytes”. Keystone Symposia, 2005. Poster presentation

27. Ilg K, Wessel J, Green J, Dyke DB, Pagani F, Day SM, Westfall MV. Expression in Failing Human Hearts. Internal Medicine Research Day, 2005.

28. Day, SM, Westfall MV, Converso KL, Sober-Rankin AM, Fomicheva EV, Metzger JM. Transgenic Expression of Cardiac Troponin I Substitution A164H Improves Long-term Performance and Attenuates Left Ventricular Remodeling in the Failing Heart. Circ 2005, 112(17) Suppl II-161:856.

29. Day SM, Lopatin A, Coutu P, Li J, Converso KL, Metzger JM. Cardiac-Directed Expression of Parvalbumin Improves Relaxation in Vivo in Two Models of Diastolic Dysfunction. Circ 2005, 112(17) Suppl II-159:842.

30. Koenig GC, Day SM, Weiss SJ. The Pericellular Collagenase MT1-MMP Regulates Post Infarction Ventricular Remodeling and Cardiac Function. Circ 2006, 114 (18) Suppl II-241:1280.

31. Day SM, Herron T, Predmore J, Converso KL, Westfall MV, Metzger JM. Histidine modified troponin I molecular switch causes reduced sarcoplasmic reticulum Ca2+ load: implications for myocardial performance during ischemia-reperfusion. Keystone Symposia, 2007. Poster presentation

32. Palpant NJ, Day SM, Converso KL, Metzger JM. Histidine substituted cardiac troponin I (A164H) improves survival and protects cardiac contractility during acute hypoxia in the aged murine heart. Circ 2007, 116(16) Suppl II-23:219.

33. Predmore J, Davis FR, Bartolone S, Pagani F, Dyke DB, Westfall MV, Wang P, Powell SR, Day SM. Proteasome dysregulation in mouse and human cardiomyopathies” Keystone Symposia, 2008. Poster presentation.

34. Predmore J, Davis F, Bartolone S, Westfall MV, Pagani F, Wang P, Osinska H, Robbins J, Powell SR, Day SM. Ubiquitin Proteasome Dysfunction in Human Cardiomyopathies. Circ Res 2008; 103(5):e48 (oral presentation for Outstanding Early-Career Investigator Award).

35. Predmore JL, Wang P, Davis FR, Bartolone S, Westfall MV, Pagani F, Dyke DB, Powell SR, Day SM. Ubiquitin Proteasome Dysfunction in Human Hypertrophic and Dilated Cardiomyopathies. American Heart Association Celebration of Science, University of Michigan Cardiovascular Center, 2009. Oral presentation.

36. Uhlmann, WR, Funke, BH, Aatre, R, Arscott, P, Gelehrter, TD, Day, SM. Genetic and Phenotypic Complexity in a Unique Family with Arrhythmogenic Right Ventricular Cardiomyopathy. Keystone Symposia, April 2009; Plenary session oral presentation.

37. Martindale JJ, Herron TJ, Day SM, Palpant NJ, Metzger JM. Dominant Effect of Histidine Modified Troponin to Normalize SR Ca2+ Load and Rescue Ischemia/Reperfusion Deficits in Phospholamban Deficient Hearts. Keystone Symposia, April 2009; Poster presentation.

38. Davis FR, Predmore JL, Pagani F, Sadayappan S, Allen D, Jones R, Day SM. Sarcomere Mutant Protein Expression in Human Hypertrophic Cardiomyopathy: Implications for Mechanism and Phenotype Severity. Keystone Symposia, March 2010: Poster presentation.


39. Kim EH, Galchev VI, Day SM, Pagani F, Kim JY, Kim Y, Misek DE, Westfall MV. Differential Proteomics Analysis in Ischemic Heart Disease. 58th American Society of Mass Spectroscopy Conference, 2010.

40. Reineck E, Baty L, Rolston B, Saberi S, Salberg L, Richardson C, Kolenic G, Sen A, Day SM. Exercise in Hypertrophic Cardiomyopathy Patients: Perceptions and Practices. Internal Medicine Research Day, University of Michigan 2010. Selected as top 10 abstract, plenary oral presentation.

41. Davis FR, Predmore J, Pagani F, Sadayappan S, Allen D, Jones R, Day SM.. Sarcomere Mutant Protein Expression in Human Hypertrophic Cardiomyopathy: Implications for Mechanism and Phenotype Severity. Internal Medicine Research Day, University of Michigan 2010. Selected as top 10 abstract, plenary oral presentation.

42. Davis FR, Predmore J, Wang P, Li J, Su H, Converso KL, Allen D, Jones R, Powell SR, Wang XJ, Day SM. Activation of the Ubiquitin Proteasome System After Myocardial Infarction. Circ 2010;122:A18730. Poster presentation.

43. Coleman DT, Davis FR, Predmore J, Bartolone S, Pagani F, Sadayappan S, Allen D, Jones R, Russell M, Day SM. Disrupted Sarcomere Stoichiometry and Heterogeneous Expression of Mutant Sarcomere Proteins in Human Hypertrophic Cardiomyopathy. Keystone symposia, February 2011: Selected as finalist for Early Independent Career Research Competition.

44. Coleman DT, Davis FR, Pagani F, Predmore J, Bartolone S, Sadayappan S, Pedersen E, Lyons R, Jones R, Russell M, Day SM. Sarcomere Gene and Protein Expression Studies Suggest Mutation-Specific Disease Mechanisms in Human Hypertrophic Cardiomyopathy. Circ 2011;124:A14422 (Oral presentation at AHA Scientific Sessions).

45. Douglas K, Predmore J, Bartolone S, Day SM. Decreased Expression of SERCA Relative to Phospholamban in Cardiac Tissue from Patients with Hypertrophic Cardiomyopathy. Internal Medicine Research Day, University of Michigan 2012. Selected as a top 10 abstract, plenary oral presentation. Awarded house officer research award.

45. Batte B, Sheldon J, Day SM, Arscott P, Huismann D, Yashar B. Utilizing Illness Representations to Improve Family Communication Within a Population At-Risk for Cardiomyopathy, National Society for Genetic Counselors National Meeting 2012.

46. Ebner B, Helms A, Day SM. Looking Past the Red Herring: A Case of Partial Anomalous Pulmonary Venous Return. Michigan American College of Physicians Annual Meeting 2012, oral presentation.

47. Maron B, Spirito P, Ackerman M, Casey S, Semsarian C, Estes M, Day SM, Formisano F, Bos JM, Maron M. Prevention of Sudden Cardiac Death with the Implantable Cardioverter-Defibrillator in Children and Adolescents with Hypertrophic Cardiomyopathy: An International Multicenter Study. Circ 2012;126:15653.

48. Gu L, Gao G, Kasturirangan S, Day SM, Dudley S. Cardiac Sodium Channel (Scn5a) mRNA Splicing Abnormalities in Hypertrophic Cardiomyopathy. Circ 2012;126:A16473.

49. Rolston B, Reineck E, Bragg-Gresham J, Salberg L, Saberi S, Baty LC, Wheeler M, Ashley E, Day SM. Patients with Hypertrophic Cardiomyopathy are Less Physically Active than the General Population. Circ 2012;126:A14837.

50. Helms A, Alvarado F, Yob J, Tang V, Bartolone S, Pagani F, Russell M, Valdivia H, Day SM. Genotype-dependent Calcium Signaling Dysregulation in Human Hypertrophic Cardiomyopathy. Keystone symposia, April 2013.

51. Benson M, Glazier A, Day SM. Identification of the Quality Control Machinery Responsible for Mediating the Proteasomal Degradation of Mutant Myosin Binding Protein C in Hypertrophic Cardiomyopathy, Internal Medicine Research Day, University of Michigan 2013. Selected as a top 10 abstract, plenary oral presentation. Awarded house officer research award.

52. McCarthy MK, Levine RE, Procario MC, Powell SR, Day SM, Weinberg JB. Immunoproteasome Activation during Mouse Adenovirus Type 1 Myocarditis, Circ 2013.

53. Day SM, Yob J, Davis FR, Wang P, Converso KL, Wang XJ, Powell SR. Selective Inhibition of the Immunoproteasome Attenuates Adverse Left Ventricular Remodeling, Improves Cardiac Function, and Prevents Heart Failure after Myocardial Infarction. Circ 2013.


54. Caliri SJ, Dewey FE, Grove M, Priest J, Shringarpure S, Pan C, Datta S, Puckelwartz M, Snyder M, Bustamante C, Day SM, McNally E, Cappola T, Dorn G, Ashley EA. Rare Variation in Sarcomeric Genes Accompanies MHY7 Hypertrophic Cardiomyopathy. Selected for late breaking science session. Circ 2013, in press.

55. Arscott P, Day SM. Truncating Mutations in Titin Associated with Left Ventricular Noncompaction in Two Unrelated Families. Heart Rhythm 2014.

56. Ebner B, Kumar S, Bragg- Gresham J, Farrehi P, Day SM. Obstructive Sleep Apnea in Hypertrophic Cardiomyopathy: Comparing Exercise Tolerance, Cardiac Remodeling, Clinical and Genetic Data. Circulation QCOR 2014.

57. Helms A, Glazier A, Bartolone S, Tang V, Yob J, Westfall M, Schnell S, Day, SM. MYBPC3 Mutations Causative for Hypertrophic Cardiomyopathy Result in Altered Protein Folding, Sarcomere Localization and Contractility. Internal Medicine Research Day, University of Michigan, 2014

58. Helms A, Glazier A, Bartolone A, Tang V, Yob J, Westfall MV, Schnell S, Day SM. MYBPC3 Mutations Causative for Hypertrophic Cardiomyopathy Result in Locus-Dependent Alterations in Cellular Localization and Contractility. Circulation 2014.

60. Glazier A, Helms A, Yob JM, Mellacheruvu D, Tang V, Bartolone S, Basrur V, Nesvizhskii AI, Day SM. Cardiac Myosin Binding Protein C Mutants Interact with and Cause Mislocalization of the Hsp70 Family of Chaperones, Circulation 2015.

61. Ho CY, Day SM, Ashley E, Michels M, Pereira C, Fox J, Caleshu C, Cirino A, Colan S, Wrolstad D. Green E, Olivotto I for the SHaRe Investigators. Examining Prevailing Genotype-Phenotype Correlations in Hypertrophic Cardiomyopathy: Findings from the Sarcomeric Hypertrophic Cardiomyopathy Registry, Circulation 2015 (Presented in Late Breaking Science Session)

62. Furqan A, Arscott P, Girobami F, Cirino A, Cichels M, Day SM, Olivotto I, Ho CY, Ashley E, SHaRe consortium, Caleshu C. Concordance in Classification of HCM variants is Markedly Higher Among Expert Centers Than Among Clinical Labs, American Society of Human Genetics 2015.

63. Glazier A, Helms A, Kotlo S, Yob U, Tang V, Day SM. Cardiac Myosin Binding Protein C Mutants Interact with Hsp70 Family Chaperones and Disrupt Protein Quality Control, Keystone Symposia 2016

64. Ho CY, Day SM, Ashley EA, Michels M, da Costa Pereira A, Fox J, Caleshu C, Colan SD, Green E, Olivotto I. Genotype, Phenotype, and Clinical Outcomes in Hypertrophic Cardiomyopathy. Keystone Symposia 2016

65. Tang V, Arscott P, Helms A, Day SM. GATA4 and LV noncompaction. Circulation 2016 Date last revision: 12/11/2016

Documents

Sharlene M. Day - Case Western Reserve University · 2017-01-10 · 7/2006 - present Director, Program for Hypertrophic and Other Inherited Cardiomyopathies 1/2013 - present Faculty,